Form 4: Tandem Diabetes Care Director Converts RSUs and Receives New Equity Grant

Kathleen McGroddy-Goetz, a Director at Tandem Diabetes Care Inc., converted 4,387 restricted stock units into common stock and was granted an additional 8,759 restricted stock units.

Summary

• Kathleen McGroddy-Goetz, a Director of Tandem Diabetes Care Inc. (TNDM), reported changes in her beneficial ownership via a Form 4 filing.
• On May 22, 2025, 4,387 Restricted Stock Units (RSUs) that were awarded on May 22, 2024, vested and were subsequently converted into 4,387 shares of common stock at an exercise price of $20.64 per share.
• Following this conversion, Ms. McGroddy-Goetz's direct beneficial ownership of common stock increased to 17,853 shares.
• Additionally, on May 21, 2025, Ms. McGroddy-Goetz was awarded a new grant of 8,759 Restricted Stock Units under the company's 2023 Long-Term Incentive Plan.
• These newly granted RSUs will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan.
• After these transactions, she beneficially owns 8,759 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a director increasing their direct shareholding through RSU conversion and receiving a new equity grant, indicating continued commitment and alignment with the company's performance. This is a routine compensation event, not a discretionary purchase, but still shows insider ownership.

Positives

• Director Kathleen McGroddy-Goetz increased her direct common stock ownership by 4,387 shares, indicating continued alignment with shareholder interests.
• The grant of an additional 8,759 Restricted Stock Units demonstrates ongoing compensation and retention of key management/directors, reinforcing their commitment to the company.

Future Outlook

The newly granted Restricted Stock Units are scheduled to vest on the one-year anniversary of their grant date, indicating future equity compensation for the director and a continued incentive for long-term performance.

Industry Context

This filing is a routine insider transaction report, common across all industries, reflecting standard equity compensation practices for directors in publicly traded companies, including those in the medical device and diabetes care sector. Such transactions are part of a director's compensation package and are generally expected.

Related Party Transactions

• The reported transactions involve a director of Tandem Diabetes Care Inc. acquiring common stock and receiving new Restricted Stock Units, which are considered related party transactions as they involve an insider's dealings with the company's securities as part of their compensation.

Stakeholder Impact

• Shareholders: The increase in a director's direct shareholding through RSU conversion may be viewed positively as it aligns the director's interests with those of shareholders. The new RSU grant is part of standard compensation, potentially diluting existing shares slightly upon vesting but also serving to retain key personnel and incentivize long-term performance.

Next Steps

• The 8,759 Restricted Stock Units granted on May 21, 2025, are expected to vest on their one-year anniversary, subject to the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Equity Grant, Director Compensation, Beneficial Ownership, Diabetes Management